Ardelyx eyes first drug approval after decade-long journey

A decade, $400 million, job cuts and two scuttled partnerships later, Ardelyx is on the cusp of delivering to patients what Raab, now chairman and CEO of the Fremont company (NASDAQ: ARDX), heard then. The Food and Drug Administration is scheduled to make a decision Thursday on whether to approve the drug, called tenapanor, for patients with irritable bowel syndrome with painful constipation.